United States - English - NLM (National Library of Medicine)

mayne pharma inc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x5 - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with nine essential vitamins. supplementation of the diet with fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. multivitamin and fluoride supplemental drops 0.25 mg provide fluoride in drop form for infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride and for children ages 3-6 years, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride. each 1.0 ml supplies sodium fluoride (0.25 mg fluoride) plus nine essential vitamins. the american academy of pediatrics recommended that infants and young children 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and children 3-6, years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.2

United States - English - NLM (National Library of Medicine)

mayne pharma inc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x5 - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with nine essential vitamins. supplementation of the diet with fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. multivitamin and fluoride supplemental drops 0.5 mg provide fluoride in drop form for infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride and for children ages 3-6 years, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride. each 1.0 ml supplies sodium fluoride (0.5 mg fluoride) plus nine essential vitamins. the american academy of pediatrics recommended that infants and young children 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and children 3-6, years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25

United States - English - NLM (National Library of Medicine)

mayne pharma inc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x5 - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with eight essential vitamins and iron, plus fluoride. supplementation of the diet with fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. multi vitamin, iron and fluoride supplemental drops 0.25 provide fluoride in drop form for children ages 2-3 years where the drinking water contains less than 0.3 ppm of fluoride and for children over 3 years, in areas where the drinking water contains 0.3 through 0.7 ppm of fluoride. each 1.0 ml provides sodium fluoride (0.25 mg fluoride) plus eight essential vitamins and iron. the american academy of pediatrics and the american dental association currently recommend that infants and children under 2 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and children 2-3, years of age, in areas where the drinking water contains 0.3 through 0.7

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that  may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of  levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with this combination product. carbidopa and levodopa may be administered co

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene cream is indicated for the topical treatment of acne vulgaris. adapalene cream should not be administered to individuals who are hypersensitive to adapalene or any of the components in the cream vehicle.

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - etonogestrel (unii: 304gth6rnh) (etonogestrel - unii:304gth6rnh), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - for vaginal use only haloette® is indicated for use by females of reproductive age to prevent pregnancy. do not prescribe haloette to women who are known to have or use the following: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: - smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] - have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] - have cerebrovascular disease [see warnings and precautions (5.1)] - have coronary artery disease [see warnings and precautions (5.1)] - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] - have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] - have uncontrolled hypertension [see warnings and precautions (5.5)] - have diabetes mellitus with vascular disease [see warnings and precautions (5.9)] - have headaches with focal neurological symptoms or migraine headaches with aura [see warnings and precautions (5.10)] women over age 35 with any migraine headaches [see warnings and precautions (5.10)] - women over age 35 with any migraine headaches [see warnings and precautions (5.10)] - liver tumors, benign or malignant or liver disease [see warnings and precautions (5.3) and use in specific populations (8.6)] - undiagnosed abnormal uterine bleeding [see warnings and precautions (5.11)] - pregnancy, because there is no reason to use chcs during pregnancy [see use in specific populations (8.1)] - current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see warnings and precautions (5.14)] - hypersensitivity reactions, including anaphylaxis and angioedema, to any of the components of haloette [see warnings and precautions (5.6) and adverse reactions (6)] - use of hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for alt elevations [see warnings and precautions (5.4)] risk summary haloette is contraindicated during pregnancy because there is no need for pregnancy prevention in a woman who is already pregnant. epidemiologic studies and meta-analyses have not shown an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following maternal exposure to low dose chcs prior to conception or during early pregnancy. no adverse developmental outcomes were observed in pregnant rats and rabbits with the administration of etonogestrel during organogenesis at doses approximately 300 times the anticipated daily vaginal human dose (~0.002 mg/kg/day). no adverse developmental outcomes were observed in pregnant rats and rabbits with the co-administration of the combination desogestrel/ethinyl estradiol during organogenesis at desogestrel/ethinyl estradiol doses at least 2/5 times, respectively, the anticipated daily vaginal human dose (~0.002 desogestrel/0.00025 ethinyl estradiol mg/kg/day). discontinue haloette use if pregnancy is confirmed. data animal data in rats and rabbits at dosages up to 300 times the anticipated dose, etonogestrel is neither embryotoxic nor teratogenic. co-administration of a maternally toxic dose of desogestrel/ethinyl estradiol to pregnant rats was associated with embryolethality and wavy ribs at a desogestrel/ethinyl estradiol dose that was 40/130 times, respectively, the anticipated vaginal human dose (0.002desogestrel/0.00025 ethinyl estradiol mg/kg/day). no adverse embryofetal effects were observed when the combination was administered to pregnant rats at a desogestrel/ethinyl estradiol dose that was 4/13 times, respectively, the anticipated vaginal human dose. when desogestrel/ethinyl estradiol was given to pregnant rabbits, preimplantation loss was observed at a desogestrel/ethinyl estradiol dose that was 3/10 times, respectively, the anticipated vaginal human dose. no adverse embryofetal effects were observed when the combination was administered to pregnant rabbits at a desogestrel/ethinyl estradiol dose that was 2/5 times the anticipated vaginal human dose. risk summary small amounts of contraceptive steroids and/or metabolites, including etonogestrel and ethinyl estradiol are transferred to human milk. harmful effects have not been observed in breastfed infants exposed to chcs through breast milk. chcs can reduce milk production in breastfeeding mothers. this is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. when possible, advise the nursing mother to use non-estrogen-containing contraception until she has completely weaned her child. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for haloette and any potential adverse effects on the breastfed child from haloette or from the underlying maternal condition. safety and efficacy of haloette have been established in women of reproductive age. efficacy is expected to be the same for postpubertal adolescents under the age of 18 and for users 18 years and older. use of this product before menarche is not indicated. haloette has not been studied in postmenopausal women and is not indicated in this population. the effect of hepatic impairment on the pharmacokinetics of haloette has not been studied. steroid hormones may be poorly metabolized in patients with impaired liver function. acute or chronic disturbances of liver function may necessitate the discontinuation of chc use until markers of liver function return to normal. [see contraindications (4) and warnings and precautions (5.3).] the effect of renal impairment on the pharmacokinetics of haloette has not been studied. haloette® (ha loe et) (etonogestrel and ethinyl estradiol vaginal ring) read these instructions for use before you start using haloette and each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your treatment. how should i start using haloette? if you are not currently using hormonal birth control, you have 2 ways to start using haloette. choose the best way for you: - first day start: insert haloette on the first day of your menstrual period. you will not need to use another birth control method since you are using haloette on the first day of your menstrual period. - day 2 to day 5 cycle start: you may choose to start haloette on days 2 to 5 of your menstrual period. make sure you also use an extra method of birth control (barrier method), such as male condoms with spermicide for the first 7 days of haloette use in the first cycle. if you are changing from a birth control pill or patch to haloette: if you have been using your birth control method correctly and are certain that you are not pregnant, you can change to haloette any day. do not start haloette any later than the day you would start your next birth control pill or apply your patch. if you are changing from a progestin-only birth control method, such as a minipill, implant or injection or from an intrauterine system (ius): - you may switch from a minipill on any day. start using haloette on the day that you would have taken your next minipill. - you should switch from an implant or the ius and start using haloette on the day that you remove the implant or ius. - you should switch from an injectable and start using haloette on the day when your next injection would be due. if you are changing from a minipill, implant or injection or from an intrauterine system (ius), you should use an extra method of birth control, such as a male condom with spermicide during the first 7 days of using haloette. if you start using haloette after an abortion or miscarriage: - following a first trimester abortion or miscarriage: you may start haloette within 5 days following a first trimester abortion or miscarriage (the first 12 weeks of pregnancy). you do not need to use an additional birth control method . - if you do not start haloette within 5 days after a first trimester abortion or miscarriage, use a non-hormonal birth control method, such as male condoms and spermicide, while you wait for your period to start. begin haloette at the time of your next menstrual period. count the first day of your menstrual period as "day 1" and start haloette one of the following 2 ways below. first day start: insert haloette on the first day of your menstrual period. you will not need to use another birth control method since you are using haloette on the first day of your menstrual period. day 2 to day 5 cycle start: you may choose to start haloette on days 2 to 5 of your menstrual period. make sure you also use an extra method of birth control (barrier method), such as male condoms with spermicide for the first 7 days of haloette use in the first cycle. - first day start: insert haloette on the first day of your menstrual period. you will not need to use another birth control method since you are using haloette on the first day of your menstrual period. - day 2 to day 5 cycle start: you may choose to start haloette on days 2 to 5 of your menstrual period. make sure you also use an extra method of birth control (barrier method), such as male condoms with spermicide for the first 7 days of haloette use in the first cycle. - following a second trimester abortion or miscarriage: you may start using haloette no sooner than 4 weeks (28 days) after a second trimester abortion (after the first 12 weeks of pregnancy). if you are starting haloette after childbirth: - you may start using haloette no sooner than 4 weeks (28 days) after having a baby if you are not breastfeeding. - if you have not gotten your menstrual period after childbirth, you should talk to your healthcare provider. you may need a pregnancy test to make sure you are not pregnant before you start using haloette. - use another birth control method such as male condoms with spermicide for the first 7 days in addition to haloette. if you are breastfeeding you should not use haloette. use other birth control methods until you are no longer breastfeeding. step 1. choose a position for insertion of haloette. - choose the position that is comfortable for you. for example, lying down, squatting, or standing with 1 leg up (see figures a, b, and c) . positions for haloette insertion step 2. open the pouch to remove your haloette. - each haloette comes in a re-sealable foil pouch. - wash and dry your hands before removing haloette from the foil pouch. - open the foil pouch at either notch near the top. - keep the foil pouch so you can place your used haloette in it before you throw it away in your household trash. step 3. prepare haloette for insertion. - hold haloette between your thumb and index finger and press the sides of the ring together (see figures d and e) . step 4. insert haloette into your vagina. - insert the folded haloette into your vagina and gently push it further up into your vagina using your index finger (see figures f and g) . - when you insert haloette it may be in different positions in your vagina, but haloette does not have to be in an exact position for it to work (see figures h and i) . - haloette may move around slightly within your vagina. this is normal. although some women may be aware of haloette in the vagina, most women do not feel it when it is in place. inserting haloette (figure f, figure g) and positioning haloette (figure h, figure i) note: - if the haloette feels uncomfortable, you may not have pushed the ring into your vagina far enough. use your finger to gently push the haloette as far as you can into your vagina. there is no danger of haloette being pushed too far up in the vagina or getting lost (see figure g). - some women have accidentally inserted haloette into their bladder. if you have pain during or after insertion and you cannot find haloette in your vagina, call your healthcare provider right away. - regularly check that haloette is in your vagina (for example, before and after intercourse) to ensure you are protected from pregnancy. step 5. how do i remove haloette? - wash and dry your hands. - choose the position that is most comfortable for you (see figures a, b, and c). - put your index finger into your vagina and hook it through the haloette. gently pull downward and forward to remove the haloette and pull it out (see figure j) . step 6. throw away the used haloette. - place the used haloette in the re-sealable foil pouch and put it in a trash can out of the reach of children and pets. - do not throw haloette in the toilet. what else should i know about using haloette? what if i leave haloette in too long? - if you leave haloette in your vagina for up to 4 weeks (28 days) you will still be getting pregnancy protection. remove your old haloette for 1 week (7 days) and insert a new haloette 1 week (7 days) later (see steps 1 through 4) . - if you leave haloette in your vagina longer than 4 weeks (28 days), remove the ring and check to make sure you are not pregnant. if you are not pregnant, insert a new haloette (see steps 1 through 4) . you must use another birth control method, such as male condoms with spermicide, until the new haloette has been used for 7 days in a row. what should i do if my haloette comes out of my vagina? haloette can slip or accidentally come out (expelled) of your vagina, for example, during sexual intercourse, bowel movements, use of tampons, or if it breaks. - haloette may break causing the ring to lose its shape. if the ring stays in your vagina this should not lower haloette's effectiveness at preventing pregnancy. if haloette breaks and slips out of your vagina, throw the broken ring in your household trash out of the reach of children and pets. insert a new haloette (see steps 1 through 4). - if haloette breaks and slips out of your vagina, throw the broken ring in your household trash out of the reach of children and pets. - insert a new haloette (see steps 1 through 4). - you should pay attention when removing a tampon to be sure that your haloette is not accidentally pulled out. be sure to insert haloette before inserting a tampon. if you accidentally pull out your haloette while using tampons, rinse your haloette in cool to lukewarm (not hot) water and insert it again right away. - be sure to insert haloette before inserting a tampon. - if you accidentally pull out your haloette while using tampons, rinse your haloette in cool to lukewarm (not hot) water and insert it again right away. - haloette can be pushed out of (expelled from) your vagina, for example, during sexual intercourse or during a bowel movement. if the expelled ring has been out of your vagina for less than 3 hours, rinse the expelled haloette in cool to lukewarm (not hot) water and insert it again right away. if the expelled haloette has been out of your vagina for more than 3 continuous hours: during weeks 1 and 2, you may not be protected from pregnancy. reinsert the ring as soon as you remember (see steps 1 through 4) . use another birth control method, such as male condoms with spermicide, until the ring has been in place for 7 days in a row. during week 3, do not reinsert the haloette that has been out of your vagina; but throw it away in your household trash away from children and pets. use another birth control method, such as male condoms with spermicide, until the new haloette has been used for 7 days in a row, following one of the two options below: - option 1. insert a new ring right away to start your next 21 day haloette use cycle. you may not have your regular period, but you may have spotting or vaginal bleeding. - option 2. insert a new ring no later than 7 days from the time the previous ring was removed or expelled. during this time, you may have your period. note: you should only choose to do option 2 if you used haloette for 7 days in a row, prior to the day that your previous haloette was accidentally removed or expelled. - if the expelled ring has been out of your vagina for less than 3 hours, rinse the expelled haloette in cool to lukewarm (not hot) water and insert it again right away. - if the expelled haloette has been out of your vagina for more than 3 continuous hours: during weeks 1 and 2, you may not be protected from pregnancy. reinsert the ring as soon as you remember (see steps 1 through 4) . use another birth control method, such as male condoms with spermicide, until the ring has been in place for 7 days in a row. during week 3, do not reinsert the haloette that has been out of your vagina; but throw it away in your household trash away from children and pets. use another birth control method, such as male condoms with spermicide, until the new haloette has been used for 7 days in a row, following one of the two options below: - option 1. insert a new ring right away to start your next 21 day haloette use cycle. you may not have your regular period, but you may have spotting or vaginal bleeding. - option 2. insert a new ring no later than 7 days from the time the previous ring was removed or expelled. during this time, you may have your period. note: you should only choose to do option 2 if you used haloette for 7 days in a row, prior to the day that your previous haloette was accidentally removed or expelled. - during weeks 1 and 2, you may not be protected from pregnancy. reinsert the ring as soon as you remember (see steps 1 through 4) . use another birth control method, such as male condoms with spermicide, until the ring has been in place for 7 days in a row. - during week 3, do not reinsert the haloette that has been out of your vagina; but throw it away in your household trash away from children and pets. use another birth control method, such as male condoms with spermicide, until the new haloette has been used for 7 days in a row, following one of the two options below: - option 1. insert a new ring right away to start your next 21 day haloette use cycle. you may not have your regular period, but you may have spotting or vaginal bleeding. - option 2. insert a new ring no later than 7 days from the time the previous ring was removed or expelled. during this time, you may have your period. - if haloette was out of the vagina for an unknown amount of time, you may not be protected from pregnancy. perform a pregnancy test prior to inserting a new ring and consult your healthcare provider. this patient information and instructions for use have been approved by the u.s. food and drug administration. distributed by: mayne pharma greenville, nc 27834 revised: 05/2022

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - tilia fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. tilia fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. tilia fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. oral contraceptives are highly effective for pregnancy prevention. table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. *  among typical couples who initiate use of a method (not ne

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c, d and fluoride 0.25 mg drops also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. vitamins a, c, d and fluoride 0.25 mg drops provide fluoride in drop form for infants and young children 6 months to 3 years of age, in areas where the drinking water contains children ages 2-3 years where the drinking water contains less than 0.3 ppm of fluoride and for children over 3 years, in areas where the drinking water contains 0.3 through 0.7 ppm of fluoride. each 1.0 ml provides sodium fluoride (0.25 mg fluoride) plus eight essential vitamins and iron. the american academy of pediatrics recommends that infants and young children under 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and; and for children ages 3-6 years, in areas where the dri

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: gelatin; povidone; cellacefate; lactose monohydrate; monobasic potassium phosphate; diethyl phthalate; erythrosine; indigo carmine; carbon black; purified water; shellac; sunset yellow fcf - indications as at 22 may 2003: eryc is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is n ot suitable prior to genitourinary or gastrointestinal tract surgery.

United States - English - NLM (National Library of Medicine)

mayne pharma commercial llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non- opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions